NEW YORK (Reuters Health) Feb 02 - Recombinant attenuated live measles virus strains derived from the Edmonston (MV-Edm) vaccine strain can effectively infect, replicate in, and kill prostate cancer cells, according to a study appearing in the current issue of The Prostate.
Oncolytic strains of measles virus represent a novel class of therapeutic agents against cancer, Dr. Evanthia Galanis of the Mayo Clinic, Rochester, Minnesota, and colleagues point out. These viruses demonstrate no cross-resistance with existing treatment approaches, and can therefore be combined with conventional treatment methods.
After demonstrating the susceptibility of prostate cancer cell lines to MV-Edm, the researchers then found that intratumoral administration of a MV-Edm vector engineered to express carcinoembryonic antigen (MV-CEA) resulted in a statistically significant delay in tumor growth (p = 0.004) and prolonged survival (p = 0.001) in a subcutaneous xenograft model of advanced (androgen-resistant) prostate cancer.
The median survival of MV-CEA-treated mice in the study nearly doubled compared to control mice, and complete tumor regression was observed in one-fifth of MV-CEA-treated animals, they report.
In a written statement, Dr. Galanis said: "Based on our preclinical results as well as the safety of measles derivatives in clinical trials against other tumor types, these viral strains could represent excellent candidates for clinical testing against advanced prostate cancer, including androgen-resistant tumors."
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου